

VPAC2 / VIPR2 Antibody (C-Terminus)
Rabbit Polyclonal Antibody
Catalog # ALS10328**Specification****VPAC2 / VIPR2 Antibody (C-Terminus) - Product Information**

Application	IHC-P
Primary Accession	P41587
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	49kDa KDa
Dilution	IHC-P~~N/A

VPAC2 / VIPR2 Antibody (C-Terminus) - Additional Information**Gene ID** 7434**Other Names**

Vasoactive intestinal polypeptide receptor 2, VIP-R-2, Helodermin-preferring VIP receptor, Pituitary adenylate cyclase-activating polypeptide type III receptor, PACAP type III receptor, PACAP-R-3, PACAP-R3, VPAC2, VIPR2, VIP2R

Target/Specificity

Human VIPR2. BLAST analysis of the peptide immunogen showed no homology with other human proteins.

Reconstitution & Storage

Long term: -70°C; Short term: +4°C

Precautions

VPAC2 / VIPR2 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

VPAC2 / VIPR2 Antibody (C-Terminus) - Protein Information**Name** VIPR2 ([HGNC:12695](#))**Synonyms** VIP2R**Function**

G protein-coupled receptor activated by the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (ADCYAP1/PACAP) (PubMed:7811244, PubMed:35477937, PubMed:8933357). Binds VIP and both PACAP27 and PACAP38 bioactive peptides with the following order of potency PACAP38 = VIP > PACAP27 (PubMed:35477937)

target="_blank">35477937, PubMed:8933357). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. Activates cAMP-dependent pathway (PubMed:7811244, PubMed:35477937, PubMed:8933357). May be coupled to phospholipase C.

Cellular Location

Cell membrane; Multi-pass membrane protein

Tissue Location

Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78


Volume

147 µl


VPAC2 / VIPR2 Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

VPAC2 / VIPR2 Antibody (C-Terminus) - Images

Anti-VPAC2 / VIPR2 antibody IHC of human Brain, Glioblastoma.



Anti-VPAC2 / VIPR2 antibody IHC of human Lung, Adenocarcinoma.



Anti-VPAC2 / VIPR2 antibody IHC of human Colon, Carcinoma.

VPAC2 / VIPR2 Antibody (C-Terminus) - Background

This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.

VPAC2 / VIPR2 Antibody (C-Terminus) - References

- Svoboda M.,et al.Biochem. Biophys. Res. Commun. 205:1617-1624(1994).
Mackay M.,et al.Genomics 37:345-353(1996).
Wei Y.,et al.J. Neuroendocrinol. 8:811-817(1996).
Lutz E.M.,et al.FEBS Lett. 458:197-203(1999).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.